Authors:
Broomfield, S. A., van der Most, R. G., Prosser, A. C., Mahendran, S., Tovey, M. G., Smyth, M. J., Robinson, B. W., Currie, A. J
Authors notes:
J Immunol (2009) 182 9 5217-24
Abstract:
Topical application of tumors with the TLR7 agonist imiquimod is an effective adjunct treatment for a range of primary dermatological cancers. However, for therapy to be effective against a broad range of solid tumor types, it must promote a strong systemic antitumor response that targets metastases in addition to primary tumor. We therefore investigated the potential of locally delivered imiquimod to stimulate an effective systemic antitumor response in a murine model of malignant mesothelioma (AB1-HA) with primary and distal tumors (dual tumor).